# Assessment of the Malaria Vaccine Candidate SumayaVac-1 in Healthy Adults Aged 18-45 Years Living in a Malaria Endemic Country

> **NCT05644067** · PHASE1 · COMPLETED · sponsor: **Swiss Tropical & Public Health Institute** · enrollment: 40 (actual)

## Conditions studied

- Malaria

## Interventions

- **BIOLOGICAL:** SumayaVac-1(SUM-101)
- **BIOLOGICAL:** Verorab

## Key facts

- **NCT ID:** NCT05644067
- **Lead sponsor:** Swiss Tropical & Public Health Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-25
- **Primary completion:** 2024-04-02
- **Final completion:** 2024-04-02
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2024-04-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05644067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05644067, "Assessment of the Malaria Vaccine Candidate SumayaVac-1 in Healthy Adults Aged 18-45 Years Living in a Malaria Endemic Country". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05644067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*